Position Trader

Swing Trading at the next level up

,

Aveanna Healthcare (AVAH) – Top Quant Stock of the Week – Shallow Dive

  • What does the company do?
  • Why Some Investors Are Bullish
  • What Bears Are Worried About
  • Why the Quants like this stock
  • My View

What does the company do?

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) is an Atlanta-based home care platform delivering patient-centered pediatric and adult healthcare services across three core segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). By transitioning care to lower-cost home settings through in-home skilled nursing, therapy, hospice care, and enteral nutrition supplies, Aveanna improves patient outcomes while mitigating the overutilization of expensive acute care facilities and hospitals. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Why Some Investors Are Bullish

  • Strong Q2 2026 results with broad-based growth — Aveanna generated $670.5 million of revenue for the quarter ended July 4, 2026, up 13.7% year over year, with growth across all three business segments. Net income increased to $40.3 million from $27.0 million, while adjusted EPS was $0.22 versus $0.17 expected, according to consensus estimates.
  • Raised full-year 2026 guidance — Management increased its 2026 revenue outlook to more than $2.68 billion, up from its previous range of $2.63 billion to $2.65 billion, and raised adjusted EBITDA guidance to more than $365 million, versus the prior range of $338 million to $342 million. The company also expects to generate at least $150 million of free cash flow for the full year.
  • Progress on preferred-payer agreements and California reimbursement — Aveanna had 37 Private Duty Services preferred-payer agreements at the end of Q2, versus its full-year goal of 38, and management expects to exceed that target. In Home Health, Aveanna reached its goal of 50 preferred-payer agreements during Q2. The company also secured a California private-duty-nursing reimbursement-rate increase scheduled to take effect January 1, 2027, following years of advocacy.
  • Improving profitability and cash generation — Six-month revenue increased 14.8% to $1.318 billion, while adjusted EBITDA rose 15.4% to $179.8 million. Free cash flow reached $75.4 million during the first six months, and net income rose to $81.9 million from $32.2 million in the prior-year period.
  • Valuation remains reasonable despite the stock’s strong rally — AVAH shares jumped approximately 24.7% on August 13 following the earnings release and have continued to appreciate since then. Even after the rally, the shares trade at roughly 14–15x forward earnings, depending on the data source, which leaves room for further upside if Aveanna can deliver on its higher earnings and cash-flow outlook.

What Bears Are Worried About

  • Gross-margin pressure remains a concern — Q2 gross margin declined to 32.6% of revenue from 35.8% a year earlier, while adjusted EBITDA margin fell to 14.2% from 15.0%. The company is growing revenue and earnings, but continued margin compression could limit how much of that top-line growth flows through to shareholders.
  • Heavy debt load — Aveanna had $1.483 billion of total indebtedness and $97.2 million of cash as of July 4, 2026. That leverage creates financial risk and could limit flexibility if reimbursement rates, labor costs, volumes or operating margins deteriorate. The company does, however, have additional borrowing capacity and an undrawn revolver.
  • Significant exposure to reimbursement rates and labor costs — Private Duty Services is Aveanna’s largest business, and the company remains heavily exposed to Medicaid and managed-care reimbursement, caregiver wages and labor availability. The California rate increase is a meaningful potential tailwind, but the fact that the increase followed years of advocacy highlights how much the economics of the business can depend on government and payer decisions outside the company’s direct control.

Why the Quants like this stock

PEG Non-GAAP (FWD) A 0.8
Revenue Growth (YoY) B 19.52%
EPS FWD Long Term Growth (3-5Y CAGR) A 21.21%
Free Cash Flow Per Share Growth Rate (FWD) A+ 93.30%
Return on Common Equity (TTM) A+ 198.57%
3M Price Performance A+ 104.08%
FY1 Up Revisions (last 90 days) 10 UP 0 Down

Latest Quarter’s Earnings
Announce Date 8/13/2026
EPS Normalized Actual $0.22 (Beat by $0.05)
EPS GAAP Actual $0.18 (Beat by $0.03)
Revenue Actual $670.48M
Revenue Surprise Beat by $31.85M

My View

Aveanna’s investment story is becoming more interesting because revenue growth is now being accompanied by meaningful profitability and free-cash-flow generation. The higher 2026 guidance, progress with preferred payers and upcoming California reimbursement increase provide potential catalysts, while margin compression and substantial leverage remain important risks to monitor. The stock’s sharp post-earnings rally also means investors now have higher expectations, making continued execution increasingly important.

All content on this site is for informational purposes only and does not constitute financial advice. Consult relevant financial professionals in your country of residence to get personalized advice before you make any trading or investing decisions. This post was written with the assistance of artificial intelligence. The original ideas and final review are human-generated. Disclaimer

Copyright 2023-2026 SwingTrader.Trading. All Rights Reserved.

←

Leave a comment